Fredun Pharmaceuticals Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Fredun Pharmaceuticals reported Q4 FY26 total income of INR213 crores, up 27.27% year-on-year, with EBITDA of INR29.13 crores and net profit of INR11.07 crores. For FY26, total income reached INR639.12 crores, a 40.08% year-on-year increase, with EBITDA of INR94.79 crores and net profit of INR33.21 crores. Management discussed growth plans for its hormonal, anti-aging, mobility, and pet care businesses, and addressed questions on raw material costs, finance costs, margins, and working capital.